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ABSTRACT 
Co-Processed Excipient (CPE) is technological innovation for tablet preparation through 
the direct compression method with a quick and straight forward manufacturing process because it 
improves the compressibility and flowability. This research aimed to formulate and evaluate of 
chlorpheniramine maleate tablets using spray dried CPE as filler and binder. The spray dried CPE 
containing MCC PH 101, and Kollidon® K30 was made into tablets through a direct compression 
method. Meanwhile, Ludipress® and Avicel® PH 102 were used as filler-binder comparators. All 
the prepared tablet formulations were then evaluated for weight variation, hardness, friability, 
disintegration time, content uniformity of active ingredient, and dissolution test. The physical 
properties of tablets with CPE as a filler and binder produced an average weight of 151.65 ± 1.53 
mg, 5.92 ± 0.38 kg of hardness, 0.06 ± 0.051% friability, 520.00 ± 2.00 seconds of disintegration 
time, and 99.24 ± 0.15% content uniformity of active ingredient. The comparators indicated better 
disintegration time than CPE (p<0.05), while the dissolution test showed that more than 80% (Q) 
of the amount of active ingredient was dissolved in 30 minutes. CPE could be successfully used to 
prepare tablet dosage form, and the tablets had fulfilled the standards of pharmacopoeia. 
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INTRODUCTION 
As the most widely used dosage form, 
oral administration, including tablets, in 
particular, accounts for 70-80% of any 
pharmaceutical preparations mainly because 
of its manufacturing simplicity, dose accuracy, 
and high level of patient compliance (Syukri et 
al., 2015). Meanwhile, despite the well-known 
significance of excipients for the success of 
pharmaceutical products, there has been only a 
minor development of new excipients. They 
are rarely introduced to the market probably 
because discovering novel excipients is 
challenging or due to the modest profit. Novel 
excipients can be produced from one of the 
following routes: new chemical entities 
developed as further excipients, new grades of 
existing excipients, or new combinations of 
existing excipients (Wang et al., 2015). 
The poor mechanical properties of active 
ingredients in a high dose make tabletting 
difficulty in tablet production, mostly forcing 
formulators to apply granulation techniques 
that provide appropriate compression 
properties of drug-excipient agglomerates. 
Direct compression (DC), however, is a 
preferable tablet manufacturing method due to 
its simplicity, rapidity, and cost-effectiveness 
(Al-Zoubi, Odeh and Nikolakakis, 2017). A 
DC process requires appropriate diluents with 
good flowability and compaction properties, 
and formerly, single-component excipients 
were physically mixed to obtain such diluents. 
Today, the basic DC process has even been 
successfully simplified by the innovative 
development of co-processed excipients 
(Aljaberi et al., 2013). 
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The new technology of co-processed 
excipients can meet the ever-increasing 
demand for excipients with multiple functions 
in DC tabletting obtained by including one 
excipient in the particle structure of another 
employing hot-melt extrusion, co-drying, co-
precipitation, or freeze-thawing. In co-
processing, the interaction between excipients 
occurs at a sub-particle level to maintain or 
develop desirable properties, improve 
functionality, and conceal undesired properties 
of each component. The characteristics and 
tabletting properties of co-processed 
excipients with multiple functions are superior 
to those of a single substance or physically-
mixed excipients concerning compatibility, 
intrinsic flow, lubricating efficiency, binding 
properties, and blending properties (Rojas and 
Kumar, 2011). Meanwhile, as an alternative to 
preparations of co-processed compressible 
powder mixture, the spray drying method is 
reportedly able to improve the compression 
properties of hypromellose and α-lactose 
monohydrate as a binder (Mužíková et al., 
2014), with erythritol, mannitol, various 
maltodextrins, crospovidone, colloidal silicon 
dioxide, polyoxyethylene 20 sorbitan 
monooleate (Gonnissen et al., 2008), HPMC, 
lactose, and PVPP (Wang et al., 2015).  
Prior to this current research, a study of 
MCC PH 101, lactose, and Kollidon® K30 as 
co-processed excipients (CPE) in spray drying 
was conducted to examine their 
compressibility as a filler and binder. The 
findings showed that spray-dried MCC PH 
101, lactose, and Kollidon® K30 could serve 
as an alternative filler and binder in a direct 
compression process, but the best CPE 
consisted of MCC PH 101 and Kollidon® K30 
only. The study showed that the optimum CPE 
had lower tapping index and higher hardness 
than the physical mixture. It indicates that the 
optimum CPE had good flowability and 
compatibility characters. Then, the optimum 
CPE also reported no chemical changes 
following the characterization through infrared 
spectrophotometer (IR), scanning electron 
microscope (SEM), differential scanning 
calorimetry (DSC), and X-ray diffraction 
(XRD) (Kusuma et al., 2017).  
This research involved chlorpheniramine 
maleate as the drug model, the first generation 
of alkylamine antihistamines commonly used 
to treat symptoms of allergies, such as rhinitis 
and urticaria(Lashkarbolooki et al., 2013). The 
appropriate method for the preparation of low-
dose chlorpheniramine maleate is the direct 
compression. While pharmacists and 
pharmaceutical companies are seeking new 
approaches to improve drug products, they 
also focus more on exploring and enhancing 
excipients with better physicochemical 
properties (Eraga et al., 2015). Therefore, 
excipient compressibility, flowability, and 
carrying capacity in tabletting should be taken 
into consideration (Dave et al., 2017).  
This study aimed to formulate tablets of 
chlorpheniramine maleate through direct 
compression with CPE as the filler-binder. 
The tablets would then be evaluated for the 
fulfilment of requirements from the 
Indonesian Pharmacopeia to control the 
quality of pharmaceutical preparations. 
 
METHODS 
Materials  
Chlorpheniramine maleate was manufactured 
by Brataco Ltd. Company Indonesia, 
Kollidon® K30 was the product of Hangzhou 
Nanhang, and microcrystalline cellulose 
(MCC PH 101) and Avicel® PH 102 came 
from Asahi Kasei Chemicals. Ludipress® was 
obtained from BASF Indonesia, and primogel, 
magnesium stearate, as well as aerosil were 
produced by Brataco Ltd. Company Indonesia. 
All the materials were of pharmacopeial 
grades, and other solvents were of analytical 
grades. 
 
CPE Preparation  
A 100-g mixture of MCC PH 101 
(79.63%) and Kollidon® K30 (20.37%) was 
suspended in 1000 ml of water to obtain a 
suspension of 10% w/v co-processed 
excipient. A spray dryer (The BUCHI Mini 
Spray Dryer B-290) with 1-mm nozzle was 
used to suck the suspension. The constant 
spray drying parameters consisted of 120°C 
inlet temperature, 4 ml/min suction speed, and 
3 Bars of pump pressure. The obtained powder 
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was then dried in an oven at 50°C for 24 
hours. Physical properties evaluation and 
characterization of CPE optimum proportions 
have been reported previously (Jacob et al., 
2007; Kusuma et al., 2017). 
 
Tablet Preparation 
Tablets were prepared from 4 mg of 
chlorpheniramine maleate with the various 
proportions of each filler and binder (CPE, 
Avicel® PH 102 and Ludipress®), 
disintegrant (Primogel), lubricant (magnesium 
stearate) and glidant (Aerosil) to attain 150 mg 
of the total quantity. All of the materials were 
homogeneously mixed, then followed by 
compression into a tablet with direct 
compression method by using the single-
punch tablet compression machine (Korsh EK 
0). The machine was set to produce diameters, 
thickness, hardness and weight in the same 
conditions. Table I shows the composition of 
three different tablet formulations.  
 
Table I. Formulations of chlorpheniramine maleate tablets with CPE (quantity for a single tablet) 
Ingredient Amount (mg) 
F1 F2 F3 
Chlorpheniramine maleate  4 4 4 
CPE 129.5 - - 
Avicel® PH 102 - 129.5 - 
Ludipress® - - 129.5 
Primogel 12 12 12 
Magnesium stearate 3 3 3 
Aerosil 1.5 1.5 1.5 
Total quantity 150 150 150 
 
Tablet Evaluation 
The parameters of tablet evaluation 
included hardness, friability, weight variation, 
and disintegration time. Weight average was 
tested according to the Indonesian 
Pharmacopeia from the measurement of the 
weight of each tablet (20 tablets in total) 
(Anonim, 1995), followed by determining the 
weight variation with the formula: the 
standard deviation is divided by the average 
weight and multiplied by 100. Ten tablets 
were tested for their hardness using a hardness 
tester (Erweka TBH 125). To determine the 
percentage of friability, ten tablets were 
weighed and then rotated at 25 rpm for 4 
minutes in a friability tester followed by the 
calculation of the total remaining weight. A 
disintegration tester (Erweka ZT 502) was 
used to individually determine the 
disintegration time of six tablets per 
formulation with aquadest at 37±0.5oC 
followed by the calculation of the mean 
disintegration time. The United States 
Pharmacopeia was referred for the content 
uniformity assessment. Ten tablets were tested 
to determine whether the concentration of 
active ingredient in each tablet ranged 
between 93% and 107% of the label claim; if 
so, the USP requirement would be claimed 
fulfilled by the batch (Anonim, 2014; United 
States Pharmacopeial Convention, 2014).  
 
In-vitro Tablet Dissolution 
The paddle stirrer of dissolution 
equipment (Erweka DT 708) was set in a 
dissolution medium (900 ml of pH 7.4 
phosphate buffer) rotating at 75 rpm and a 
maintained temperature of 37±0.5oC. Then, 
using a fitted pre-filter syringe, 5 ml 
dissolution medium sample was taken at 
specific time intervals, and the drug release 
was analyzed based on the absorbance 
measured at 262 nm. The current quantity of 
dissolution medium was used to replace the 
volume taken at each interval of time, and then 
the calculation and time plotting of the 
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percentage of released chlorpheniramine 
maleate were performed (Anonim, 2014; 
United States Pharmacopeial Convention, 
2014). 
 
RESULTS AND DISCUSSION 
Tablet Evaluation 
Table II shows the evaluation results for 
chlorpheniramine maleate tablets with 
different fillers-binders. The parameters 
include hardness, weight variation, 
disintegration time, active-ingredient content 
uniformity, and friability in formulations 
containing CPE (F1), Avicel® PH 102 (F2), 
and Ludipress® (F3).  
Table II. Results of chlorpheniramine-maleate tablet evaluation with various fillers and binders 
Evaluation F1 F2 F3 
Weight variation (mg) 151.65 ± 1.53 151.55 ± 0.6 150.05 ±0.6 
Weight variation, CV (%) 0.4 1.01 0.4 
Diameter (mm) 7.04 ± 0,00 7.09 ± 0.00 7.07 ± 0.00 
Thickness (mm) 3.48 ± 0.02 3.77 ± 0.01 2.93 ± 0.04 
Hardness (kg) 5.92 ± 0.38 6.57 ± 0.35 4.73 ± 1.11 
Friability (%) 0.06 ± 0.051 0.09 ± 0,033 0.09 ± 0.07 
Disintegration time (sec) 520.00 ± 2.00 15.67 ± 2.08 131.33 ± 6.43 
Content uniformity (%) 99.24 ± 0.15 97.88 ± 0.10 98.87 ± 0.17 
 
Weight variation is evaluated to guarantee 
the right amount of active ingredient in each 
of the tablets. The weights variations of each 
formulation with optimum CPE (F1), Avicel® 
PH 102 (F2), and Ludipress® (F3) were 0.4%; 
1.01%; and 0.4%, respectively, indicating a 
small variation. All of the formulations had 
<1% friability with the longest disintegration 
time in the formulation containing CPE. As 
the time remained below 900 seconds, the 
formulations were considered meeting the 
criteria determined in the Indonesian 
Pharmacopeia (Anonim, 1995). 
Weight variation is affected by flow 
properties and equipment conditions during 
the study. In addition, SEM analysis showed 
that Kollidon® K30 was invisible as it had 
enveloped Avicel® PH 102 (Kusuma et al., 
2017), thereby enhancing the flow properties 
of the excipients. In evaluating the uniformity 
of tablet size, the parameters evaluated were 
tablet diameter and thickness. The results of 
the uniformity evaluation of the size were F1 
with a diameter of 7.04 mm and 3.48 mm 
thick; F2 with a diameter of 7.07 mm and a 
thickness of 3.77 mm and F3 with a diameter 
of 7.09 mm and thickness of 2.93 mm. Factors 
that can influence uniformity in size are flow 
velocity, mixture homogeneity, and punch 
press stability. This uniformity of size is 
related to the die diameter used and the 
amount of powder entering the die. A good 
size criterion is: if a tablet has a diameter of 
not less than 1 1/3 and is not more than 3 
times the thickness of the tablet (Anonim, 
1979).  
In addition, tablets should be strong 
enough to withstand mechanical shocks while 
they are manufactured, packaged, shipped, and 
dispensed, which can be fulfilled when the 
hardness falls between 4 and 8 kg with <1% 
friability (United States Pharmacopeial 
Convention, 2014). Table II indicates that the 
hardness and friability of all of the formulated 
tablets have met the mechanical property 
criteria. The investigation could be clarified 
that MCC showed low elastic recovery and 
good compressibility. This condition will 
reduce tablet failures, include sticking, 
capping, lamination and binding (Osamura et 
al., 2016). 
According to the Pharmacopeia, 1% 
maximum mass loss or 0.8% - 1.0% weight 
loss should be fulfilled by tablets tested for 
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crushing strength without laminating, capping, 
or breaking during the test. Tablet crushing 
strength can greatly influence the rate of drug 
release. The increased crushing strength of a 
tablet generally means the decreased rate of 
drug release because of reduced porosity of 
the tablet (Eraga et al., 2015). Differences in 
the profiles of drug release are likely caused 
by the changes in crushing strength 
experienced by the tablet batches studied 
(Komersová et al., 2016). 
Evaluation should also be done for the 
disintegration time, which is the time required 
by a tablet to completely break down and 
penetrate the basket mesh in a disintegration 
test. Such tests represent the process of a tablet 
breaking down into particles in the 
gastrointestinal tract, which, according to the 
Indonesian Pharmacopeia, should last no 
longer than 15 minutes for an uncoated tablet 
(Anonim, 2014), and the tablet disintegration 
time in this research has fulfilled the 
requirement.  
Tablets containing optimum CPE as the 
filler-binder are influenced by their hardness 
and friability as well as the nature of 
Kollidon® K30 as the CPE component. Such 
component will turn into gel when it interacts 
with water, thus trapping other components 
and preventing them from dissolving, which 
consequently results in longer disintegration 
time. Meanwhile, tablets with Avicel® PH 
102 as the filler-binder have shorter 
disintegration time because such component 
has multiple functions as a filler, binder, and 
disintegrant. 
Content uniformity test is conducted to 
ensure the fulfilment of the standard for active 
ingredient concentration in a tablet, which will 
influence the results of a therapy. For 
chlorpheniramine maleate tablets, the 
concentration of active ingredient should 
range from 93% to 107% (Anonim, 2014). 
Both powder homogeneity and weight 
uniformity affect the concentration of active 
ingredient in tablets. This study found that the 
concentrations of chlorpheniramine maleate in 
Formulation 1, 2, and 3 reached 97.88%, 99%, 
and 98.87%, respectively. 
 
In-vitro Tablet Dissolution  
To determine the concentration of active 
ingredient dissolved in a medium, a 
dissolution test is performed in vitro. Tablet 
dissolution is strongly influenced by the 
disintegration time, which will also affect the 
bioavailability. Figure 1 shows the dissolution 
profile of chlorpheniramine-maleate tablets 
with CPE (F1), Avicel® PH 102 (F2), and 
Ludipress® (F3) as the fillers-binders. 
 
Figure 1. Dissolution characteristics of chlorpheniramine maleate tablets containing different fillers and binders 
    (n = 6) 
The formulation with CPE as the filler-
binder has 80% dissolved active ingredient 
with longer disintegration time compared to 
the other formulations. The use of Kollidon® 
K30 as a component of CPE in tablets affects 
the disintegration time since such component 
naturally forms a gel mass that obstructs the 
release of the active ingredient. However, all 
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of the formulations in this research had met 
the dissolution criteria defined by the 
Indonesia Pharmacopoeia (Anonim, 2014). 
This finding is also supported by previous 
research, which showed that HPMC co-
processed filler prepared by fluid bed coating 
and spray drying has the potential to be 
developed as a filler and binder in direct 
compression method (Dong et al., 2018). Co-
processed excipients also facilitate direct 
compression of orally disintegrating tablets. 
Multifunctional excipients exhibited more 
dominant impact on the investigated tablet 
properties, especially for tablet disintegration 
properties (Drašković et al., 2018). 
 
CONCLUSION 
The CPE comprising MCC PH 101 and 
Kollidon® K30 as a filler and binder in tablet 
formulation can improve the compressibility 
of chlorpheniramine maleate tablets prepared 
using the direct compression method. The 
physical properties of a tablet with CPE as the 
filler-binder were 0.4 weight variation, 
5.92±0.38 kg hardness, 0.06±0.051% 
friability, 520.00±2.00 seconds of 
disintegration time, and 99.24±0.15% content 
uniformity of active ingredient. Therefore, the 
tablets had fulfilled the standards of 
pharmacopoeia. 
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